Year |
Citation |
Score |
2019 |
Pairawan S, Hess KR, Janku F, Sánchez NS, Shaw KRM, Eng C, Damodaran S, Javle M, Kaseb AO, Hong DS, Subbiah V, Fu S, Fogelman DR, Raymond VM, Lanman RB, et al. Cell-Free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31852833 DOI: 10.1158/1078-0432.Ccr-19-0306 |
0.329 |
|
2018 |
Sanchez NS, Bailey AM, Wathoo C, Balaji K, Demirhan ME, Yang D, Kahle M, Kaseb AO, Javle MM, Eng C, Subbiah V, Janku F, Raymond VM, Lanman RB, Shaw KR, et al. Identification of actionable genomic alterations utilizing cfDNA. Journal of Clinical Oncology. 36: 12110-12110. DOI: 10.1200/Jco.2018.36.15_Suppl.12110 |
0.333 |
|
2018 |
Pairawan SS, Hess KR, Janku F, Sanchez NS, Eng C, Damodaran S, Javle MM, Kaseb AO, Hong DS, Subbiah V, Fu S, Fogelman DR, Raymond VM, Lanman RB, Meric-Bernstam F. Cell-free circulating tumor DNA somatic alteration burden and its impact on survival in metastatic cancer. Journal of Clinical Oncology. 36: 12022-12022. DOI: 10.1200/Jco.2018.36.15_Suppl.12022 |
0.303 |
|
2016 |
Carugo A, Genovese G, Seth S, Nezi L, Rose JL, Bossi D, Cicalese A, Shah PK, Viale A, Pettazzoni PF, Akdemir KC, Bristow CA, Robinson FS, Tepper J, Sanchez N, et al. In Vivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5-Myc Association as a Critical Determinant of Pancreatic Cancer. Cell Reports. PMID 27320920 DOI: 10.1016/J.Celrep.2016.05.063 |
0.368 |
|
2016 |
Clark CR, Robinson JY, Sanchez NS, Townsend TA, Arrieta JA, Merryman WD, Trykall DZ, Olivey HE, Hong CC, Barnett JV. Common pathways regulate type III TGFβ receptor-dependent cell invasion in epicardial and endocardial cells. Cellular Signalling. PMID 26970186 DOI: 10.1016/J.Cellsig.2016.03.004 |
0.468 |
|
2015 |
Pettazzoni P, Viale A, Shah P, Carugo A, Ying H, Wang H, Genovese G, Seth S, Minelli R, Green T, Huang-Hobbs E, Corti D, Sanchez N, Nezi L, Marchesini M, et al. Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer. Cancer Research. 75: 1091-101. PMID 25736685 DOI: 10.1158/0008-5472.Can-14-1854 |
0.365 |
|
2015 |
Viale A, Pettazzoni P, Lyssiotis C, Ying H, Sánchez N, Marchesini M, Carugo A, Green T, Seth S, Giuliani V, Heffernan T, Kimmelman A, Wang H, Fleming J, Cantley L, et al. Abstract PR13: Pancreatic tumor stem cells resistant to inhibition of oncogenic signaling are dependent on mitochondrial function Cancer Research. 75. DOI: 10.1158/1538-7445.Panca2014-Pr13 |
0.447 |
|
2015 |
Kapoor A, Yao W, Ying H, Hua S, Liewen A, Sadanandam A, Al-Khalil R, Viale A, Pettazzoni P, Sanchez N, Protopopov A, Zhang J, Heffernan T, Johnson RL, Chin L, et al. Abstract A94: Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Panca2014-A94 |
0.4 |
|
2014 |
Viale A, Pettazzoni P, Lyssiotis CA, Ying H, Sánchez N, Marchesini M, Carugo A, Green T, Seth S, Giuliani V, Kost-Alimova M, Muller F, Colla S, Nezi L, Genovese G, et al. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature. 514: 628-32. PMID 25119024 DOI: 10.1038/Nature13611 |
0.44 |
|
2014 |
Kapoor A, Yao W, Ying H, Hua S, Liewen A, Wang Q, Zhong Y, Wu CJ, Sadanandam A, Hu B, Chang Q, Chu GC, Al-Khalil R, Jiang S, Xia H, ... ... Sanchez N, et al. Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer. Cell. 158: 185-97. PMID 24954535 DOI: 10.1016/J.Cell.2014.06.003 |
0.407 |
|
2014 |
Kapoor A, Yao W, Ying H, Hua S, Liewen A, Wang Q, Zhong Y, Wu C, Sadanandam A, Hu B, Chang Q, Chu G, Al-Khalil R, Jiang S, Xia H, ... ... Sanchez N, et al. Abstract PR01: Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer Molecular Cancer Research. 12. DOI: 10.1158/1557-3125.Rasonc14-Pr01 |
0.396 |
|
2012 |
Hill CR, Sanchez NS, Love JD, Arrieta JA, Hong CC, Brown CB, Austin AF, Barnett JV. BMP2 signals loss of epithelial character in epicardial cells but requires the Type III TGFβ receptor to promote invasion. Cellular Signalling. 24: 1012-22. PMID 22237159 DOI: 10.1016/J.Cellsig.2011.12.022 |
0.744 |
|
2012 |
Sánchez NS, Barnett JV. TGFβ and BMP-2 regulate epicardial cell invasion via TGFβR3 activation of the Par6/Smurf1/RhoA pathway. Cellular Signalling. 24: 539-48. PMID 22033038 DOI: 10.1016/J.Cellsig.2011.10.006 |
0.736 |
|
2011 |
Sánchez NS, Hill CR, Love JD, Soslow JH, Craig E, Austin AF, Brown CB, Czirok A, Camenisch TD, Barnett JV. The cytoplasmic domain of TGFβR3 through its interaction with the scaffolding protein, GIPC, directs epicardial cell behavior. Developmental Biology. 358: 331-43. PMID 21871877 DOI: 10.1016/J.Ydbio.2011.08.008 |
0.73 |
|
2007 |
Ray S, Xu F, Li P, Sanchez NS, Wang H, Das SK. Increased level of cellular Bip critically determines estrogenic potency for a xenoestrogen kepone in the mouse uterus. Endocrinology. 148: 4774-85. PMID 17640991 DOI: 10.1210/En.2007-0537 |
0.311 |
|
Show low-probability matches. |